A group of synthetic compounds formed by the aldolic reaction of isatins and kojic acid have been studied as inhibitors of PDK. This new family of compounds, 3-hydroxy-3-[3-hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl] indolin-2-ones (compound
64 in
Figure 2), have been proven to have different biomedical applications, such as anticonvulsant, anti-inflammatory, and anti-cancer effects.
2.2.7. Compounds in Combination with Other Therapies
Particularly, a binary prodrug named PDOX (compound 65 in Figure 2) was designed and investigated. It consisted of a combination of DCA (PDK inhibitor) and the anti-cancer drug doxorubicin (DOX). The prodrug was activated selectively by cancer-associated esterase to deliver DCA and DOX.
The PDK inhibitor DCA (compound 44) has also been explored in lung cancer in combination with commercial therapeutic drugs, particularly A549 and LNM35. Al-Azawi and co-workers demonstrated that DCA significantly enhanced the anti-cancer effect of cisplatin, gefitinib, and erlotinib. The additive effects on the inhibition of the mentioned cell lines due to the synergistic effect were shown.
Alongside the drug combination approach, new evidence for the synergism between the PDK inhibitor DCA and the HIF-1α inhibitor PX-478 was found. The group demonstrated that the combination of DCA and PX-478 produced synergistic effects in colorectal, lung, breast, cervical, liver, and brain cancer cell lines.
2.3. PK Modulators
2.3.1. Small Molecules
Small molecules include molecules that activate the enzyme, along with others that can trigger PKM2 and promote different mechanisms that inhibit tumor growth.
TEPP-46 and DASA-58 (compounds
66 and
67 in
Figure 3), two allosteric activators, were studied in five breast cancer cell lines to investigate the potential effect of PKM2 when it is activated. The studies showed that the molecules were able to increase the activity of the enzyme in those cancer cells without affecting the overall cell survival and that they were also able to reduce an intracellular glucose sensor (TXNIP levels)
[43].
Figure 3. Chemical structures of the PK modulators.
2.3.2. Polyphenolic Compounds
The evaluation of these phenolic compounds against three binding sites of PKM2 provides insight into how molecule–enzyme binding occurs and functionally how amino residues of PKM2 are important. These compounds have different IC50 values and can exert anti-tumor effects in different cancer cell lines.
Ellagic acid (compound
68 in
Figure 3) is an organic heterotetracyclic compound and is found in numerous fruits and vegetables
[44]. Ellagic acid can induce apoptosis in MCF-7 and MDA-MB-231 cancer cells and can induce a reduction in the key glycolytic enzymes, such as PKM2, HK2, and GLUT1, which were measured in MCF-7 and MDA-MB-231 cells. It induced apoptosis in those cancer cell lines with IC
50 values of 23 µM and 27 µM, respectively
[45].
Silibinin (compound 69 in Figure 3) is the principal component of silymarin, a standardized extract of silybum marianum. It is well known due to its chemo-preventive, anti-angiogenic, and apoptosis inducer properties. It has been identified as a potent PKM2 inhibitor with an IC50 value of 0.91 µM. It can reduce PKM2 and the protein in TNBC cells (MDA-MB-231 and BT549 cells) and induce a reduction in the key glycolytic enzymes, such as PKM2, HK2, and GLUT1.
Resveratrol (compound 18 in Figure 3) is a natural stilbene and non-flavonoid polyphenol that can be found in cereals, fruits, and vegetables. It has been demonstrated that it possesses antioxidant, anti-inflammatory, anti-tumoral, and cardioprotective effects.
Curcumin (compound
16 in
Figure 3) has been studied as an anti-cancer compound. It has been demonstrated that curcumin inhibited the glucose uptake and lactate production in the H1299 (lung), MCF-7 (breast), HeLa (cervical), and PC-3 (prostate) cancer cell lines by downregulating the PKM2 expression via the inhibition of the mTOR-HIF-1α axis
[46].
HCA (compound
70 in
Figure 3) is an active component isolated from cinnamon bark. It inhibits the PKM2 and STAT3 signaling pathways. Its biochemical methods (affinity chromatography, drug affinity, responsive stability assay, etc.) demonstrated that HCA bound directly to PKM2 and decreased the protein kinase activity of the enzyme by decreasing the phosphorylation at the tyrosine 105 residue
[47].
This section highlights the various flavonoids derived from vegetables and fruits, which have demonstrated antiproliferative effects on human cancer cells.
Apigenin (compound
71 in
Figure 3) inhibits cancer cell proliferation by triggering cell apoptosis and modulating the cell cycle. It interferes with multiple signaling pathways and protein kinases (PI3K/AKT, MAPK/ERK, JAK/STAT, NF-κB and Wnt/β-catenin)
[48]. Apigenin targeted and reduced the PKM2 enzyme expression and activity in colon cancer cells (HCT-116, HT-29, and DLD1)
[49].
Other flavones, such as diosmetin and chrysin (compounds
72 and
73 in
Figure 3), have been studied due to their structural features, showing their capacity to inhibit the PKM2 enzyme. This interruption of glycolysis resulted in a reduction in tumor growth
[50].
2.3.3. Quinoline Derivatives
Quinoline derivatives (NZT) have been the subject of syntheses, structure–activity relationships, selectivity, and other properties research. Certain studies focused on the 2-oxo-
N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide scaffold (compound
74 in
Figure 3). These studies revealed an EC
50 value of 90 nM with a significant selectivity over other PK isoforms
[51].
In silico studies confirmed that the 8-quinolinesulfonamide derivatives, concretely compound 79 (compound
75 in
Figure 3), were potential PKM2 modulators. In vitro research studies showed that this compound could reduce the intracellular pyruvate level in A549 lung cancer cells, reduce cell viability, and induce apoptosis
[52].
2.3.4. Nonsteroidal Anti-Inflammatory Drugs
Salicylic acid (SA) (compound
76 in
Figure 3) is the major and active metabolite of aspirin. Both compounds are well-described drugs that can be used without the need of a prescription for lowering fever, reducing inflammation, and relieving low to moderate pain.
2.3.5. Miscellanea
Benserazide (BEN) (compound 24 in Figure 3) is currently in clinical use as a co-adjuvant treatment in Parkinson’s disease with L-DOPA. It has been demonstrated, first by a structure-based virtual ligand screening in an FDA-approved drug database and then by in vitro and in vivo studies, that BEN was able to direct PKM2 binding, hence blocking its activity. In this way, the aerobic glycolysis concurrent upregulation of OXPHOS can be inhibited in a dose-dependent manner.
N-(4-(3-(3-(methylamino)-3-oxopropyl)-5-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-1-yl)phenyl)propiolamide (compound 77 in Figure 3) is a novel irreversible PKM2 inhibitor that has demonstrated tumor suppressive effects in different cell lines. This compound can inhibit PKM2 by interacting with CYS326 and CYS317 of the enzyme and the propiolamide electrophile terminus of compound 77. The inhibition of the enzyme and, as result, the growth suppression of the tumor was tested in PC9 cells where the PKM2 expression was shown to be decreased.
Valproic acid (compound
78 in
Figure 3) has been found to reduce the PKM2 expression in breast cancer cells, specifically in MCF-7 and MDA-MB-231 cells
[53].
Vitamin K compounds, known as VKs, are fat-soluble compounds. VK3 (compound
79 in
Figure 3) and VK5 (compound
80 in
Figure 3) have been reported to be adjuvant agents for cancer therapy. Chen et al., demonstrated that these vitamins acted as selective PKM2 inhibitors in Hela cells
[54][55].
Lapachol (compound 81 in Figure 3), a compound derived from Tabebuia impetiginosa, has been shown to have a greater affinity compared to other related natural products, such as shikonin, which was demonstrated using computer-aided design.
Glyotoxin (compound
82 in
Figure 3) bound directly and strongly to PKM2 and suppressed its activity. Moreover, it exhibited a dose-dependent inhibition of glycolytic activity, resulting in a reduced glucose consumption and lactate production within the U87 human glioma cell line. The inhibition of PKM2 activity further led to the suppression of STAT3 phosphorylation. These studies demonstrated the potential of gliotoxin as a treatment for glioma by targeting cancer metabolism
[56].
Boronic acid has the ability to activate the PKM2 enzyme, leading to redox metabolism in oral cancer cells. Consequently, a novel class of boronic acid derivatives was developed. Particularly, the PKM2 activity of compound
83 (
Figure 3) was tested in CAL-27 cells. It was found that compound
83 activated PKM2 with an AC50 of 25 nM
[57].
Dihydroartemisinin (DHA) (compound
84 in
Figure 3), also known as artenimol, is an active metabolite of the anti-malarial drug artemisinin. DHA induces a pro-inflammatory cell death called pyroptosis. It has been shown to downregulate the PKM2 expression and induce cell death in the esophageal squamous cell carcinoma (ESCC) cells Eca109 and EC9706 at 24 h. DHA has the potential to be a therapeutic agent for ESCC by downregulating the PKM2 expression, activating the caspase-8/3-GSDME axis, and mediating tumor cell pyroptosis
[58].
The antipsychotic medication Pimozide (compound 85 in Figure 3) acts on the signaling pathway and promotes the effect of p53, leading to a decrease in the expression of PKM2. Pimozide has demonstrated strong anti-breast cancer effects both in vitro and in vivo.
Compound 86 (Figure 3) is a specific inhibitor of the PKM2 enzyme. Investigations on the anti-cancer effects of this inhibitor were conducted using MTT and colony formation assays in SK-OV-3 cells. Compound 86 was found to induce AMPK activation, which is associated with suppressing the tumor progression. The inhibition of PKM2 by compound 86 affected the Warburg effect and led to autophagic cell death.
NPD10084 (compound
87 in
Figure 3) has demonstrated an antiproliferative activity against colorectal cancer cells both in vitro and in vivo. In this study, PKM2 was identified as a potential target protein for this compound. Interestingly, NPD10084 disrupted the protein–protein interactions between PKM2 and β-catenin or STAT3, leading to the suppression of the downstream signaling pathways
[59].
The cinnamaldehyde derivative (CB-PIC) (compound 35 in Figure 3), the major component of cinnamon, has been found to inhibit the migration of H1299 lung tumor cells in scratch and transwell assays. This compound was directly and specifically bound to recombinant PKM2, resulting in a reduction in its catalytic activity. The cells with PKM2 knockdown demonstrated a significantly reduced migration compared to the control cells when subjected to glucose and oxygen deprivation. The anti-cancer mechanism of compound 35 was investigated in human HCC cells in relation to STAT3 signaling.
In addition, a literature-based phytochemical analysis of Mangifera indica identified a total of 94 compounds, which were docked against three binding sites of PKM2 to identify the potential PKM2 inhibitors. Among these compounds, berberine (compound 88 in Figure 3), isolated from Coptis and Hydrastis canadensis, was found to inhibit the PKM2 activity, showing antiproliferative effects in HCT116 and HeLa cells.
A novel sulfonamide compound with a pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety has been identified as a potent activator of PKM2. A series of analogs based on the lead compound 89 (Figure 3) were designed and synthetized. Among these analogs, compounds 90 and 91 (Figure 3) demonstrated higher PKM2 activation activities. Furthermore, they exhibited more significant antiproliferative effects against human tumor cell lines.
2.4. LDH Enzyme Modulators
2.4.1. Small Molecules
Sodium oxamate (compound
92 in
Figure 4) exerted a competitive inhibition of human LDHA in vitro with a Ki of 136.3 uM in two NPC cancer cell lines. However, this derivative presented several problems related to a low and limited selectivity, weak potency, and poor cellular uptake
[60]. The studies showing the MOA
[61] stated that compound
92 could promote cell apoptosis via the downregulation of the CDK1/cyclin B1 pathway, which ultimately provoked the inhibition of LDHA.
Figure 4. Chemical structures of the LDH modulators.
2.4.2. Pyridazine and Piperazine
Trimetazidine (TMZ) (compound
93 in
Figure 5) is a drug indicated exclusively in adults as additional therapy for the symptomatic treatment of patients with stable angina pectoris. Silica-induced pulmonary fibrosis studies in rats were done to explore the effects of this drug over the LDH activity. The results showed that the derivative of compound
93 was able to reduce and normalize the levels of the enzyme in bronchoalveolar lavage fluid (BALF)
[62]. TMZ can be used alone or in combination with antineoplastic drugs, such as gemcitabine or abraxane, to reduce cell viability and induce apoptosis in human pancreatic cancer cells
[63].
Pyridazine derivatives exhibited potent anti-cancer activity and were synthesized due to structure-based virtual screening studies. Compound
94 (
Figure 5) exerted its effect on multiple cancer lines: Med1-MB (a cell line obtained from Sonic Hedgehog medulloblastoma), CRC HCT116, SW620, lung cancer A549, and pancreatic PANC-1 cancer cell lines.
2.4.3. Polyphenols
Epigallocatechin (EGCG) (compound
95 in
Figure 4) is one of the main compounds of green tea and a compound found in the medical plant
Spatholobus suberectus, which is commonly used in China for the treatment of cancer-related blood stasis.
FX11 (3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid) (compound
96 in
Figure 4) is a synthetic molecule that was discovered using an HITS assay. FX11 is structurally related to gossypol and is well known to be a sensitizer in chemotherapy-resistant tumor cells
[64][65][66].
Gossypol (compound 97 in Figure 4) is a natural aldehyde derived from cotton seed and it can inhibit several cancer cell lines, such as melanoma, lung, breast, cervix, and leukemia.
Galloflavin (compound
98 in
Figure 4), a synthetic derivative of gallic acid, binds to LDHA, but it is also able to block LDHB without competing with substrates and cofactors. The cytotoxic effects were demonstrated by this analog in various human breast cancer cells (MCF-7, triple-negative MDA-MB-321, and tamoxifen-resistant MCF-7tam cell lines)
[64][67].
2.4.4. Quinoline-Based Derivatives
Compound
99 (
Figure 4) a quinoline 3-sulfonamide derivative, is a selective and competitive LDHA inhibitor, competing with NADH. This derivative can exert its effect in multiple cell lines, including hepatocellular and breast carcinomas
[68].
2.4.5. Sulfide and Disulfide Derivatives
GNE-140 (compound
100 in
Figure 4), a synthetic molecule discovered using an HITS assay, was tested in MDA-MB-231 and HCC143 cells in vitro. GNE-140 has been demonstrated to block LDH
[69].
Several substituted 3-hydroxy-mercaptocyclo-2-enone compounds, especially compound
101 (
Figure 4), have been identified as potent novel class LDH inhibitors using the HITS approach. Compound
101 can bind to the active site of LDH where pyruvate usually binds, hence limiting and competing with the substrate binding.
2.4.6. Nonsteroidal Anti-Inflammatory Compounds
Diclofenac (compound 102 in Figure 4) is commonly used to reduce inflammation and alleviate pain. Apart from its classical role as a cyclooxygenase (COX) inhibitor, diclofenac has exhibited potent anti-cancer effects. Studies were conducted to investigate whether diclofenac could induce cancer cell death in HeLa cells through the production of ROS.
2.4.7. Compounds in Combination with Other Therapies
Different concentrations of METABLOC (compound 103 in Figure 4), a combination of hydroxycitrate and lipoic acid, was used in combination with diclofenac and metformin in LL/2 lung carcinoma cells. Cisplatin was used as a positive control. The effects of METABLOC appeared to be enhanced when high-dose metformin was used.
In another study, the combination of diclofenac (
102 in
Figure 4) and ibuprofen was examined. Both drugs are NSAIDs associated with anti-tumoral effects in glioma cells. However, ibuprofen showed a stronger inhibition of cell growth compared to diclofenac. Both drugs were able to decrease STAT3 phosphorylation. Interestingly, diclofenac led to a decreased C-MYC expression and a subsequent reduction in the LDHA activity.
2.4.8. Miscellanea
Crocetin (compound
104 in
Figure 4) is a 20-carbon dicarboxylic acid diterpenoid that was obtained using chemical synthesis. Its LDH inhibition properties have been tested against two cancer cell lines (A549 and HeLa)
[70][71].
Machillin A (compound
105 in
Figure 4), a natural product found mainly in
Machilus thunbergii,
Iryanthera lancifolia, and
Magnolia sinica, has been demonstrated to reduce tumor growth by inhibiting LDHA. It is a competitive inhibitor, which blocks the NAD binding site
[70][72].
Nifurtimox (compound
106 in
Figure 4), a drug used for treating parasitic protozoan
Trypanosoma cruzi infections, has also been reported to present cytotoxic properties in the neuroblastoma cell lines LA-N-1, IMR-32, LS and SK-N-SH. Nifurtimox can achieve a reduction in the LDH enzyme activity
[73].
N-hydroxyndole-based inhibitors have been demonstrated to be small, competitive, and LDHA isoform-selective inhibitors. The derivative of compound
107 (
Figure 4) can compete against pyruvate and NADH. SAR studies confirmed the importance of the OH-COOH pharmacophore, since the enzyme active site will usually have a gap for lactate (hydroxyl group) and another for pyruvate (alpha-keto acid group)
[74].
Selenobenzenes, such as (1-(phenylseleno)-4-(trifluoromethyl)benzene (PSTMB) (compound 108 in Figure 4), demonstrated their ability to decrease tumor growth in several tumor cell lines (NCI-H460, MCF-7, Hep3B, A375, HT-29, and LLC).
Oxaloacetate (OAA) (compound 109 in Figure 4) is a competitive inhibitor of human LDHA and has been found to be regulated by PKM2 activity. An elevated PKM2 activity can promote the de novo synthesis of OAA through glutaminolysis, leading to the inhibition of LDHA in cancer cells.
N-acylhydrazone derivatives have been studied as LDHA inhibitors. For this purpose, a virtual screening procedure was conducted. Afterwards, chemical modifications were made to the selected compounds to enhance their inhibitory activity. The new molecules demonstrated activity in the micro-molar range. Specifically, compound 110 (Figure 4) exhibited a significant effect on lactate production in the Raji human cell line.